drugset
drugset / Trial / NCT04238364

A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy Volunteers

NCT04238364 ↗

Phase 1 Completed 58 enrolled Elixiron Immunotherapeutics Inc. Parexel · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This was a first-in-human study to determine the safety, tolerability, and pharmacokinetics of EI1071 after single and multiple doses in healthy volunteers.

Timeline

Start
2019-12-27
Primary completion
2021-12-16
Completion
2022-01-10

Drugs

EvaluationDrugModalityDoseRoute
Subject ENRUPATINIB Small molecule — Oral

Indications

No indication recorded.